---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-047544"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:03:38.788962+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger

## Summary
- As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.
- Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.
- Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.
- Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.
- May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet.

## SEC filing metadata
- accession: 0001193125-26-047544
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/0001193125-26-047544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/d89820d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-047544
- JSON: https://secwatch.observer/filing/0001193125-26-047544.json
- Plain text: https://secwatch.observer/filing/0001193125-26-047544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.